PepsRadar
⌕ Search✧ Ask
A dated record of additions and corrections, with the reason for each change and links back to the work.
History begins October 4, 2026. These initial entries document the current library release, not newly published medical discoveries. Entries are recorded when editorial work is published; there is no automatic research monitoring.
· Visual update
Original conceptual artwork now appears on eight profiles and their directory cards. The coordinated teal, sea-glass, and copper images are labeled as AI-generated concepts; sourced molecular figures remain separate.
Why it matters: Make browsing more visual without presenting editorial artwork as a scientific structure or evidence of an outcome.
Explore the change →· Product knowledge
Supplier-specific ingredient amounts, identity discrepancies, and selected ingredient research are now linked from the catalog. GLOW and KLOW labels are not treated as proof of a shared chemical identity or tested combination.
Why it matters: Distinguish the supplier formulation from individual peptides and preserve uncertainty about exact-blend evidence.
Explore the change →· Evidence expansion
A new early-development profile separates mouse and human findings. Expanded profiles include the negative phase 3 exenatide Parkinson result, tesamorelin liver-fat research, and clearer lanreotide and pramlintide benefit and harm measures.
Why it matters: Keep negative findings, study populations, absolute versus relative changes, and open questions alongside benefits. These are selected abstract-based notes and have not been reviewed by a medical professional.
Explore the change →· Evidence expansion
STEP 4 and SURMOUNT-4 distinguish run-in loss from randomized-period change and explain selection of lead-in completers. LIXIPARK adds a separate neurological research question for lixisenatide, with gastrointestinal harms and phase 2 limitations.
Why it matters: Deepen existing profiles rather than infer broad benefits from mechanisms. These are newly indexed summaries of earlier publications, not new medical discoveries.
Explore the change →· Evidence expansion
The directory now covers 65 peptides and 78 selected publications. New profiles include metabolic dual agonists, endocrine medicines, immune research, and circulation-related peptides. Full-length thymosin beta-4 and GHK are separate from TB-500 and GHK-Cu.
Why it matters: Expand coverage with original, source-linked notes that preserve populations, negative findings, safety context, and product identity. Source-check date is not a publication date.
Explore the change →· Library feature
Original artwork for 13 research areas, an at-a-glance section on each profile, and a shared search for peptides, selected studies, guides, topics, and video records.
Why it matters: Makes the existing sources easier to find and understand. Searchable videos remain distinct from medically reviewed evidence.
Explore the change →· Evidence expansion
The library now links 58 selected publications. New summaries include negative and inconclusive results, related-compound identity limits, and separate human observations from mouse interventions.
Why it matters: Adds study-specific context to frequently discussed peptides. This is an editorial expansion of older papers, not eleven new scientific discoveries.
Explore the change →· Library baseline
The existing selected study summaries can now be filtered by peptide and evidence type, with population, design, findings, limitations, and publication links together.
Why it matters: Makes the reviewed scope easier to inspect. This is a library feature release, not an announcement of new study results.
Explore the change →· Reviewed excerpts
Existing reviewed caption excerpts now have timestamp links, editorial questions, and related evidence cards. The MOTS-c numerical claim retains an unresolved source label.
Why it matters: Separates what a speaker said from what a selected paper supports. Related papers are not automatically the speaker’s sources.
Explore the change →· Page update
Individual 2D illustrations and interactive 3D views are available. Computed conformers, the experimental insulin structure, and three schematic exceptions are labeled separately.
Why it matters: Makes molecular identity visible without implying that every illustration is a validated biological fold.
Explore the change →· Supplier documentation
The report linked under directory reference 261469 identifies batch 3-3-46143 and certificate COA261565. The listed laboratory and report date are now searchable.
Why it matters: Directory reference, certificate identifier, and batch number are distinct fields. Authentication and current-stock matching remain unverified.
Explore the change →